Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to tackle obesity: early trial tests how the body handles the drug

NCT ID NCT05841238

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-stage study tests an experimental oral drug called LY3502970 in healthy adults who are overweight or obese. The main goal is to see how the drug enters the bloodstream and how the body clears it, as well as to check for any safety issues. Participants will take the drug in tablet or capsule form, and the study also looks at how food affects the drug. Results will help decide whether to move forward with larger trials for weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3502970 (oral drug)
What this could lead to
If successful, this could lead to a new oral medication for weight management in people who are overweight or obese.
What could go wrong
This is a very early (Phase 1) study focused on safety and drug levels, not weight loss. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

52 people

The number who actually took part.

Started

Apr 2023

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants who are overtly healthy as determined by medical evaluation * Participants with body mass index (BMI) of 27.0 kilograms per meter squared (kg/m²) or more * Participants with a stable body weight, with 5% or less body weight gain or loss Exclusion Criteria: * Have any type of diabetes with hemoglobin A1c (HbA1c) level of 6.5% or greater or a fasting blood sugar over 120 milligram per deciliter (mg/dL) * Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome * Have known clinically significant gastric emptying abnormality * Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass) * Known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug * Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy OBESE

Contacts and locations

Locations

  • LabCorp CRU, Inc.

    Daytona Beach, Florida, 32117, United States

  • LabCorp CRU, Inc.

    Madison, Wisconsin, 53704, United States

  • Labcorp Clinical Research LP

    Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.